This week on Second Opinion, Christina Farr and Luba Greenwood discuss the acquisition of 23andMe by Regeneron, the involvement of Hims and Hers in the GLP-1 market, and two significant IPOs in the digital health sector.
One tiny fund I hadn’t heard of absolutely crushed it
In this episode of Second Opinion, Christina Farr, Stephen Klasko and Jessica Beegle, discuss the persistent challenges in healthcare despite
This is a hot topic and I’ve heard plenty of arguments with both sides. Here’s my POV.
This week on Second Opinion, Christina Farr and Ash Zenooz interview Stephen Buck, CEO/Co-Founder of Courage Health.
More perspectives from experienced operators on the great build vs. buy question for fundamental technology used by digital health cos
Lets compare the s-1s of two interesting digital health companies are going public in 2025
This week on Second Opinion, we're sharing an episode from Peter Lee's Microsoft Research Podcast with guests Dave deBronkart and Christina Farr.
Employers tell me that preventative health is harder than ever
This week on Second Opinion, Christina Farr and Ash Zenooz interview Seraphina Therapeutics CEO Steph Venn-Watson, unpacking why men dominate the longevity space, the cellular secrets of aging, and C15:0’s potential to boost health.
